CX213 can be applied to acute inflammatory damage, and can simultaneously scavenge various kinds of reactive oxygen species by using inorganic, oxide-based, nanocatalytic functions. Clinical applicability has been verified through vigorous experimentation.
One CX213 particle has multiple reaction centers, which can all scavenge various reactive oxygen species. Additionally, the excellent surface area to volume ratio, which is characteristic of nanoparticles, ensures a maximum therapeutic effect with a low volume of particles.
Several studies have shown that biocompatibility increases by coating the surface of CX213 with a polymeric compound. CX213 has a large therapeutic index: the toxic dose is more than 100 times the therapeutic dose.
Traditional antioxidants can only scavenge certain types of reactive oxygen species, but CX213 can scavenge all known reactive oxygen species.
CX213 could lead to an expansion of indicators for a variety of diseases in which the pathophysiology is related to reactive oxygen species.
CX213 for treatment of acute inflammatory injury
In acute inflammatory injury, excessive reactive oxygen species (ROS) are produced.
It is too large amount to be eliminated by an endogenous antioxidant in the body, resulting severe acute inflammatory responses.
Damage of brain cells and tissue
CX213 for treatment of subarachnoid hemorrhage
Main target disease: SAH
SAH is a subtype of stroke that causes bleeding due to damaged large arteries on the surface of the brain, mostly caused by a rupture of intracranial aneurysms.
The acute inflammatory response is triggered by reactive oxygen species caused by toxic component of extravasated blood, resulting severe neurological deficit or death.
Up to 10% of patients die even before arriving at the hospital, and 25% of patients die within 24 hours. Despite the best medical treatment, the 6-month mortality rate reaches up to 50%.
Current clinical guidelines recommend surgery or endovascular treatment for repair of ruptured aneurysms, but this only prevents further bleeding and does not solve widespread acute inflammation caused by extravasated blood, which leads to high mortality.
The efficacy of CX213 was investigated by applying a randomized, investigator-blinded clinical trial design in the subarachnoid hemorrhage animal model. The CX213-treated group significantly increased survival rate as 3 times more than the control group.
Identification of survival rate
Cenyx Biotech inc. and one other, “New cerium oxide nanocomposite and its use”, 10-2020-0036974, 2020.3.26
3 times higher survival rate